Assays noncompetitive

Bl. Barnard, G., and Kohen, R, Idiometric assay Noncompetitive immunoassay for small molecules typified by the measurement of estradiol in serum. Clin. Chem. 36, 1945-1950 (1990). 

Also recently, Liao and collaborators [89] proposed a homogeneous noncompetitive assay of a protein in biological samples based on FRET by using its tryptophan residues as intrinsic donors and its specific fluorescent ligand as the FRET acceptor, which was defined as an analytical FRET probe. To evaluate this method, a naphthylamine derivative, namely /V-biotinyl-/V -(l -naphthylj-ethylene-diamine (BNEDA) 33 was used as an analytical FRET probe for the homogeneous noncompetitive assay of streptavidin. 

Liao F, Xie Y, Yang X et al (2009) Homogeneous noncompetitive assay of protein via Forster-resonance-energy-transfer with tryptophan residue(s) as intrinsic donor(s) and fluorescent ligand as acceptor. Biosens Bioelectron 25 112-117... 

Irreversible inhibitors may be distinguished graphically from reversible noncompetitive inhibitors by plotting Vmax versus [E]t, where [E]t represents the total units of enzyme activity in the assay. For a noncompetitive inhibitor, the slope of the curve in the presence of inhibitor will be less than that of the control plot, and the plot will pass through the origin. If the inhibitor is instead irreversible, the slope of the curve in the presence of inhibitor will be identical to that of the control data, and the line will intersect the horizontal [E]t axis at a point equivalent to the concentration of enzyme irreversibly inactivated (Segel, 1993). 

ELISA assays may be competitive or noncompetitive. As the name imphes, in a competitive ELISA, enzyme-labeled antigen competes with free antigen (the analyte of interest) for a fixed and limited quantity of immobihzed antibody binding sites. After incubation, the microtiter plate (sohd support) is rinsed to remove all unbound species and the enzyme substrate is added in saturating concentration. The conversion of substrate to produce can be measured continuously (kinetic assay) or, more commonly. 

Noncompetitive ELISA methods are based on sandwich assays in which an excess supply of immobilized primary antibody, the capture antibody, quantitatively binds the antigen of interest and an enzyme-labeled secondary antibody is then allowed to react with the bound antigen forming a sandwich. A color reaction product produced by the enzyme is then used to measure the enzyme activity that is bound to the surface of the microtiter plate. Sandwich ELISA (noncompetitive) methods yield calibration curves in which enzyme activity increases with increasing free antigen concentration. 

Three important classes of inhibitors are shown in Table 1-8-3. Competitive inhibitors resemble the substrate and compete for binding to the active site of the enzyme. Noncompetitive inhibitors do not bind at the active site. They bind to regulatory sites on the enzyme. Irreversible inhibitors inactivate the enzyme similar to removing enzyme from the assay. 

The rate equation to be used for kinetic analysis of enzyme depletion is that for simple noncompetitive inhibition. If the Henderson equation or similar types are not employed, keep in mind that the inhibitor concentration [I] is the free inhibitor concentration. Determination of Ki may not be feasible if the rate assay is insensitive and requires an enzyme concentration much greater than K[. Alternatively, Ki may be obtained by measuring the on-off rate constants of the E l complex, provided the rate constants for any conformation change steps involved are also known. 

Fig. 3. Schematic representation of noncompetitive immunoassays. (A) Two-site immunometric assays (sandwich assays) and (B) single-antibody (single-epitope) immunometric assays.

Fig. 4. Classification of reported noncompetitive immunoassays for haptens based on the assay principle. (A) Assays that include a chemical modification of hapten to allow sandwich-type detection. (B1) Improved single-antibody immunometric assays that separate immune complex and excess labeled antibody, either by using a hapten-immobilized affinity column or based on differences in their physical properties. (B2) A variation of single-antibody immunometric assays based on masking of unoccupied antibody by an immunoreactive macromolecule followed by selective capture and detection of the hapten-occupied antibody. (C) Assays employing a probe molecule specific to a hapten-antibody complex.

This assay procedure has been applied to various haptens having a primary amino group, including leukotriene C4 (VI), T4 (P2), substance P (P2), endothelin (P2), and AGII (G2) (for structures, see Fig. 5A and 5C). These noncompetitive assays were 10-300-fold more sensitive than corresponding competitive assays (G2). The minimal detectable concentrations described in these papers were as follows 2 pg/ml ( 0.3 fmol/assay) for leukotriene C4, 14 pg/ml ( 0.2 fmol/assay) for T4, 6 pg/ml ( 0.4 fmol/assay) for substance P, and 20 pg/ml ( 0.8 fmol/assay) for endothelin. 

Several noncompetitive assays for haptens reported so far can be regarded as variations of conventional single-antibody immunometric assays, the majority of which (the assays in Sections 3.1 and 3.2) are based on principle B1 in Fig. 4. In many cases, these methods employ an automated flow system to simplify the assay procedure and minimize the time and labor required for the analysis. 

Self (S4) first proposed the concept of noncompetitive assay for haptens utilizing an adequate combination of an a-type and a jS-type anti-idiotype antibody, in which he used the term, selective antibody for the a-type antibodies. Then, Barnard and Cohen (Bl) applied this assay principle for the determination of serum E2, naming the assay system an idiometric assay. Figure 12A illustrates the assay procedure of the idiometric assay of E2. The target hapten is captured by excess anti-E2 antibody immobilized on microtiter strips by incubation at room temperature for 1 h (step i). After washing the strips, the /3-type anti-idiotype antibody was added in order to saturate (or block) the unoccupied paratope of the anti-E2 antibody (incubation, room temperature for 30 min) (step ii). The a-type anti-idiotype antibody, which has been labeled with a europium chelate (H4), was then added to the plate and incubated at room temperature for a further 2 h (step iii). Finally, fluorescence intensity due to bound europium was measured with a time-resolved fluorometer. Because of large steric hindrance around the bound jS-type antibody (MW 150,000), the labeled a-type antibody would. 

We (K1) attempted to develop a noncompetitive assay based on the anti-idiotype antibodies for a conjugated bile acid metabolite, ursodeoxycholic acid 7-A-acetyl-glucosaminide (UDCA 7-NAG), which is expected to serve as a diagnostic index for an autoimmune disease, primary biliary cirrhosis. In our assay, the hapten UDCA 7-NAG, a /3-type antibody, and a biotin-labeled a-type antibody were simultaneously added to a microtiter plate coated with an F(ab )2 fragment of a specific anti-UDCA 7-NAG antibody, then incubated at room temperature for 8 h. Bound biotin was then detected with HRP-labeled streptavidin, whose enzyme activity was measured using o-phenylenediamine/H202 as a substrate. This noncompetitive assay system provided a subfemtomole-order sensitivity (detection limit 118 amol) that was 7 times lower than the competitive immunoassay using the same anti-hapten antibody (K2), even with a common colorimetric detection (Fig. 13). Somewhat improved specificity was also obtained namely, better... 

As reported by Seif (S6), the /3-type antibody can be replaced with a macro-moiecuie muitiply iabeied with the target hapten, such as hapten-carrier conjugates used for immunogen. The noncompetitive assay for cortisoi (Gl), which was discussed in Section 3.3, is based on this principle, but employs a different method for selective detection of hapten-occupied antibody. 

Using an antibody specifically recognizing the antigen-antibody complex, more direct noncompetitive hapten immunoassays, which can be regarded as semi two-site immunometric assay, could be established (S3). Figure 14 depicts two typical procedures of noncompetitive assays using anti-metatype antibodies, which are based on principle C in Fig. 4. 

---